TN2014000243A1 - Benzopyrannes nouveaux, compositions les contenant et leurs utilisations - Google Patents

Benzopyrannes nouveaux, compositions les contenant et leurs utilisations

Info

Publication number
TN2014000243A1
TN2014000243A1 TNP2014000243A TN2014000243A TN2014000243A1 TN 2014000243 A1 TN2014000243 A1 TN 2014000243A1 TN P2014000243 A TNP2014000243 A TN P2014000243A TN 2014000243 A TN2014000243 A TN 2014000243A TN 2014000243 A1 TN2014000243 A1 TN 2014000243A1
Authority
TN
Tunisia
Prior art keywords
methyl
benzopyranes
novel
compositions containing
containing same
Prior art date
Application number
TNP2014000243A
Other languages
English (en)
Inventor
Peter J Kushner
David C Myles
Cyrus L Harmon
Leslie Carol Hodges Gallagher
Original Assignee
Olema Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48613277&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2014000243(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Olema Pharmaceuticals Inc filed Critical Olema Pharmaceuticals Inc
Publication of TN2014000243A1 publication Critical patent/TN2014000243A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Il est proposé des benzopyrannes ayant une puissante activité anti-oestrogénique et qui n'ont pratiquement aucune activité oestrogénique, qui sont le OP-1038, consistant en le 3-(4-hydroxyphényl) -4-méthyl-2- (4-(2-(3R)-3-méthylpyrrolidine-1-yl) éthoxy)phényl) -2H-chromène-7-ol, et le OP-1074, qui consiste en le (2S) -3-(4-hyroxyphényl) -4-méthyl-2-(4-(2(3R) -3-méthyl-pyrrolidine-1-yl) éthoxy)phényl) -2H-chromène-7-ol. Le OP-1074 est un anti-œstrogène pur lorsqu'il est testé en mode agoniste et un anti-œstrogène total lorsqu'il est testé en mode antagoniste. Ces composés sont utiles pour le traitement ou la prévention de diverses affections qui sont modulées par le récepteur d'oestrogènes chez des mammifères, y compris les êtres humains.
TNP2014000243A 2011-12-16 2014-06-03 Benzopyrannes nouveaux, compositions les contenant et leurs utilisations TN2014000243A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161576890P 2011-12-16 2011-12-16
PCT/US2012/070168 WO2013090921A1 (fr) 2011-12-16 2012-12-17 Nouveaux composés benzopyranes, compositions et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
TN2014000243A1 true TN2014000243A1 (fr) 2015-09-30

Family

ID=48613277

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2014000243A TN2014000243A1 (fr) 2011-12-16 2014-06-03 Benzopyrannes nouveaux, compositions les contenant et leurs utilisations

Country Status (27)

Country Link
US (2) US9018244B2 (fr)
EP (1) EP2791128A4 (fr)
JP (1) JP2015505856A (fr)
KR (1) KR20140103335A (fr)
CN (1) CN104169266A (fr)
AP (1) AP2014007657A0 (fr)
AU (1) AU2012353660A1 (fr)
BR (1) BR112014014767A2 (fr)
CA (1) CA2857061A1 (fr)
CL (1) CL2014001533A1 (fr)
CR (1) CR20140259A (fr)
CU (1) CU20140066A7 (fr)
DO (1) DOP2014000135A (fr)
EA (1) EA201490897A1 (fr)
EC (1) ECSP14009619A (fr)
HK (1) HK1199246A1 (fr)
IL (1) IL233118A0 (fr)
MA (1) MA35722B1 (fr)
MD (1) MD20140054A2 (fr)
MX (1) MX2014007198A (fr)
NI (1) NI201400057A (fr)
PE (1) PE20150099A1 (fr)
PH (1) PH12014501237A1 (fr)
SG (1) SG11201402564QA (fr)
TN (1) TN2014000243A1 (fr)
WO (1) WO2013090921A1 (fr)
ZA (1) ZA201404733B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627692T3 (es) 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Moduladores de receptores de estrógenos y usos de los mismos
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
WO2014203129A1 (fr) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinaisons de composés benzopyrane, leurs compositions et utilisations
WO2014203132A1 (fr) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Composés de benzopyran substitués, leurs compositions et utilisations
CN104725333A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种新的氮杂环庚烷衍生物的制备方法
CA2940576A1 (fr) * 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Combinaisons therapeutiques avec des modulateurs du recepteur des ƒstrogenes
EP3116496A1 (fr) * 2014-03-13 2017-01-18 F. Hoffmann-La Roche AG Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes
WO2017024318A1 (fr) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Dégradation de protéines ciblées destinée à atténuer une thérapie par transfert adoptif de cellules t associée des réponses inflammatoires indésirables
JP6776348B2 (ja) 2015-10-01 2020-10-28 オレマ ファーマシューティカルズ インク． テトラヒドロ−１Ｈ−ピリド［３，４−ｂ］インドール抗エストロゲン薬物
SG11201803119XA (en) 2015-10-27 2018-05-30 Sun Pharma Advanced Res Co Ltd Novel heterocyclic antiestrogens
AU2016366680B2 (en) 2015-12-09 2021-06-24 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulators
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197046A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles
EP3454856A4 (fr) 2016-05-10 2019-12-25 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
EP3858835A1 (fr) 2016-07-01 2021-08-04 G1 Therapeutics, Inc. Agents antiprolifératifs à base de pyrimidine
KR102623130B1 (ko) 2016-10-11 2024-01-10 듀크 유니버시티 Er+ 유방암의 라소폭시펜 치료
WO2018081168A2 (fr) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Répresseurs du récepteur oestrogénique sélectifs mixtes à base de benzothiophène
CN110177554B (zh) 2017-01-06 2023-06-02 G1治疗公司 用于治疗癌症的组合疗法
CN111386263A (zh) 2017-02-08 2020-07-07 达纳-法伯癌症研究所有限公司 调节嵌合抗原受体
US10208011B2 (en) 2017-02-10 2019-02-19 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
CA3067873A1 (fr) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Formes morphiques de g1t38 et leurs procedes de fabrication
WO2019079569A1 (fr) 2017-10-18 2019-04-25 Novartis Ag Compositions et méthodes pour la dégradation sélective d'une protéine
TW202000658A (zh) 2018-02-16 2020-01-01 美商星座製藥公司 P300/cbp hat 抑制劑及其使用方法
US11414384B2 (en) 2018-02-16 2022-08-16 Constellation Pharmaceuticals, Inc. P300/CBP hat inhibitors
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
EP3897631A4 (fr) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. Dégradation ciblée de protéines
TW202045492A (zh) 2019-02-27 2020-12-16 美商星座製藥公司 P300/cbp hat抑制劑及其使用方法
WO2020219742A1 (fr) 2019-04-24 2020-10-29 Novartis Ag Compositions et procédés de dégradation sélective de protéines
KR20220046586A (ko) 2019-07-22 2022-04-14 썬 파마 어드밴스트 리서치 컴패니 리미티드 선택적 에스트로겐 수용체 분해제
JP2022542421A (ja) 2019-07-29 2022-10-03 コンステレーション・ファーマシューティカルズ・インコーポレイテッド 神経障害の治療に使用するための化合物
CN113045546A (zh) * 2021-03-25 2021-06-29 浙江天宇药业股份有限公司 一种吡咯替尼杂质、其制备方法及用途
WO2024030968A1 (fr) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Composés pour moduler la protéine ret
WO2024097980A1 (fr) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Inhibiteurs de protéines ret-ldd
WO2024097989A1 (fr) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Agents de dégradation de protéine ret-ldd

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5686465A (en) 1988-10-31 1997-11-11 Endorecherche Inc. Sex steroid activity inhibitors
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5254568A (en) 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5446061A (en) 1993-11-05 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
US5416098A (en) 1993-12-30 1995-05-16 Zymogenetics, Inc. Method for treating dermatitis and related conditions
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5446071A (en) 1994-11-18 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
US5637598A (en) 1994-11-18 1997-06-10 Eli Lilly And Company Methods of inhibiting bone loss
US5980938A (en) 1996-07-15 1999-11-09 Eli Lilly And Company Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1)
AU8102398A (en) 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
WO1999028344A2 (fr) 1997-11-28 1999-06-10 Innogenetics N.V. Peptides synthetiques contenant une citrulline reconnue par les serums de malades atteints de polyarthrite rhumatoide comme des outils de diagnostic et de traitement
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
DE69905376T2 (de) 1998-08-14 2003-10-09 Schering Corp Enanthioauswählende synthese
US6262270B1 (en) 1998-08-14 2001-07-17 Schering Corporation Enantioselective synthesis
WO2000037083A1 (fr) 1998-12-18 2000-06-29 Schering Corporation Composition pharmaceutique orale anti-oestrogenique
US6638727B1 (en) 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
AU5957500A (en) 1999-07-06 2001-01-22 Endorecherche Inc. Methods of treating and/or suppressing weight gain
WO2001026651A2 (fr) 1999-10-14 2001-04-19 Endorecherche, Inc. Modulateurs selectifs des recepteurs oestrogeniques pour traiter l'hypertension, des maladies cardio-vasculaires et la resistance a l'insuline ou reduire le risque de contracter ces maladies
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
WO2001054699A1 (fr) 2000-01-28 2001-08-02 Endorecherche, Inc. Modulateurs selectifs du recepteur d'oestrogene, en combinaison avec des oestrogenes
DE10013782A1 (de) * 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
WO2003041654A2 (fr) 2001-11-14 2003-05-22 Sirbasku David A Combinaisons d'antioestrogenes et d'immunomudulateurs pour traiter le cancer du sein
JP4554219B2 (ja) 2002-04-24 2010-09-29 メルク・シャープ・エンド・ドーム・コーポレイション エストロゲン受容体調節剤
WO2004091488A2 (fr) 2003-04-14 2004-10-28 Merck & Co., Inc. Modulateurs des recepteurs d'oestrogenes
CN102357248A (zh) 2004-10-20 2012-02-22 恩多研究公司 单独的性甾体前体或与选择性***受体调节剂联合用于防治绝经后女性的***疾病和病症
BRPI0703735A2 (pt) 2007-08-29 2009-09-15 Endorech Inc aperfeiçoamento em composto opticamente ativo ou sal farmaceuticamente aceitável do mesmo e composição contendo o referido composto
US20090082467A1 (en) 2007-09-21 2009-03-26 Harry Fisch Treatment of migraine headaches using antiestrogens
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
PT3124481T (pt) 2010-02-16 2018-06-18 Aragon Pharmaceuticals Inc Moduladores do receptor de androgénios e suas utilizações
ES2627692T3 (es) * 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Moduladores de receptores de estrógenos y usos de los mismos
US11576891B2 (en) 2010-06-16 2023-02-14 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
SG10201610249TA (en) 2012-06-07 2017-02-27 Aragon Pharmaceuticals Inc Crystalline forms of an androgen receptor modulator
BR122017017921A2 (pt) 2012-07-27 2019-09-10 Aragon Pharmaceuticals Inc métodos e sistema para determinar a resistência à terapia de receptor de androgênio
NZ744456A (en) 2012-09-26 2019-09-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته

Also Published As

Publication number Publication date
AP2014007657A0 (en) 2014-05-31
ZA201404733B (en) 2016-04-28
MD20140054A2 (ro) 2014-10-31
CU20140066A7 (es) 2014-10-02
ECSP14009619A (es) 2015-09-30
CR20140259A (es) 2014-08-21
CA2857061A1 (fr) 2013-06-20
US20130178445A1 (en) 2013-07-11
JP2015505856A (ja) 2015-02-26
EP2791128A4 (fr) 2015-04-22
IL233118A0 (en) 2014-08-03
MA35722B1 (fr) 2014-12-01
EA201490897A1 (ru) 2015-03-31
PH12014501237A1 (en) 2014-09-08
NI201400057A (es) 2014-10-01
WO2013090921A1 (fr) 2013-06-20
HK1199246A1 (en) 2015-06-26
KR20140103335A (ko) 2014-08-26
DOP2014000135A (es) 2014-08-31
US9018244B2 (en) 2015-04-28
CN104169266A (zh) 2014-11-26
MX2014007198A (es) 2014-10-13
AU2012353660A1 (en) 2014-06-12
SG11201402564QA (en) 2014-09-26
CL2014001533A1 (es) 2014-10-17
US20150197506A1 (en) 2015-07-16
PE20150099A1 (es) 2015-01-30
EP2791128A1 (fr) 2014-10-22
BR112014014767A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
TN2014000243A1 (fr) Benzopyrannes nouveaux, compositions les contenant et leurs utilisations
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
UA109173C2 (uk) Склад, що містить фунгіцидний штам і хімічну сполуку
EA200601895A1 (ru) 3-(4-гетероарилциклогексиламино)циклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
MA32711B1 (fr) Pyrrolidine-2-carboxamides substitues
EA201000089A1 (ru) Применение гомо- и сополимеров для стабилизации составов активных ингредиентов
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
ATE469895T1 (de) Cgrp-rezeptorantagonisten
ATE445609T1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
EA200602242A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
EA201170676A1 (ru) Агонисты рецептора меланокортина
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
NZ592382A (en) Thioamide compounds, method of making and method of using thereof
MA33836B1 (fr) Compositions pharmaceutiques contenant des ligands des récepteurs sigma
ATE552246T1 (de) Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
NZ604975A (en) Synergistic active ingredient combinations containing penflufen
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
WO2011138310A3 (fr) Méthodes de prévention et de lutte contre les infections pathogènes chez les abeilles, et composition associée
MA38410B1 (fr) Composés d'azétidinyloxyphénylpyrrolidine